Modern approaches to osteoarthritis therapy taking into account updated international guidelines
A.M. Lila, L.I. Alekseeva, E.A. Taskina
V.A. Nasonova Scientific Research Institute of Rheumatology, Moscow
Osteoarthritis (OA) is a chronic progressive joint disease, presenting a serious medical and social problem. The disease is associated with increased mortality risk and requires therapy as early as possible. The article analyzes modern treatment tactics in OA proposed by experts of the European League Against Rheumatism (EULAR), the Osteoarthritis Research Society International (OARSI) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). According to current guidelines, patient treatment should be carried out using a combination of non-pharmacological and pharmacological methods. ESCEO experts noted that currently non-drug interventions in OA are not sufficiently implemented in practical health care, and it is necessary to improve the organization of their implementation in the future. The arti cle discusses approaches to basic OA therapy, including symptomatic slow-acting drugs for osteoarthritis (SYSADOA), discusses the effectiveness and safety of paracetamol, non-steroidal anti-inflammatory drugs, intra-articular administration of hyaluronic acid and glucocorticosteroids, as well as pain relief in patients with severe pain syndrome. Total knee replacement is recommended only for patients with the last stage of OA. A step-by-step algorithm for prescribing therapy in OA is proposed, which will be useful for practitioners.
Keywords: osteoarthritis, modern therapy, guidelines, comorbidity, symptomatic slow-acting drugs, SYSADOA, chondroitin sulfate, Alflutop.
For citation: Lila A.M., Alekseeva L.I., Taskina E.A. Modern approaches to osteoarthritis therapy taking into account updated international guidelines. RMJ. Medical Review. 2019;11(II):48–52.
References
1. Балабанова Р.М., Дубинина Т.В., Демина А.Б., Кричевская О.А. Заболеваемость болезнями костно-мышечной системы в Российской Федерации за 2015–2016 гг. Научно-практическая ревматология. 2018;56(1):15–21. [Balabanova R.M., Dubinina T.V., Demina A.B., Krichevskaya O.A. The incidence of diseases of the musculoskeletal system in the Russian Federation for 2015–2016 Scientific and practical rheumatology. 2018;56(1):15–21 (in Russ.)].
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, аnd years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789–1858. DOI: 10.1016/S0140-6736(18)32279-7.
3. Мартынов А.И., Наумов А.В., Верткин А.Л. и др. Ведение больных с остеоартритом и коморбидностью в общей врачебной практике: мнение экспертов, основанное на доказательной медицине. Лечащий врач. 2015;04:39–46. [Martynov A.I., Naumov A.V., Vertkin A.L. et al. Management of patients with osteoarthritis and comorbidity in general medical practice: expert opinion based on evidence-based medicine. Therapist. 2015;04:39–46 (in Russ.)].
4. Veronese N., Cereda E., Maggi S. et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016 Oct;46(2):160–167. DOI: 10.1016/j.semarthrit.2016.04.002.
5. Kovari E., Kaposi A., Bekes G. et al. Comorbidity clusters in generalized osteoarthritis among female patients: A cross-sectional study. Semin Arthritis Rheum. 2019 Sep 9. pii: S0049–0172(19)30233–1. DOI: 10.1016/j.semarthrit.2019.09.001.
6. McAlindon T.E., Bannuru R.R., Sullivan M.C. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363–388. DOI: 10.1016/j.joca.2014.01.003.
7. Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578–1589. DOI: 10.1016/j.joca.2019.06.011.
8. Bruyere O., Cooper C., Pelletier J.P. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014; 44(3):253−263.
9. Bruyère O., Cooper C., Pelletier J.P. et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3–11. DOI: 10.1016/j.semarthrit.2015.11.010.
10. Bruyère O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. Semin Arthritis Rheum. 2019 Apr 30. pii: S0049–0172(19)30043–5. DOI: 10.1016/j.semarthrit.2019.04.008.
11. Gregori D., Giacovelli G., Minto C. et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA 2018;320(24):2564–2579. DOI: 10.1001/jama.2018.19319.
12. Lo Y.L., Sung K.H., Chiu C.C., Wang L.F. Chemically conjugating polyethylenimine with chondroitin sulfate to promote CD44-mediated endocytosis for gene delivery. Mol Pharm. 2013Feb 4;10(2):664–676. DOI: 10.1021/mp300432s. Epub 2013 Jan 14.
13. Духанин А.С. Симптом-модифицирующие препараты замедленного действия в лечении остеоартрита: от молекулы к клиническому эффекту (взгляд фармаколога). Современная ревматология. 2018;12(2):79–87. DOI: 10.14412/1996-7012-2018-2-79-87.
14. Reginster J.Y., Dudler J., Blicharski T., Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017;76(9):1537–1543. DOI: 10.1136/annrheumdis-2016-210860.
15. Алексеева Л.И., Шарапова Е.П., Таскина Е.А. и др. Многоцентровое слепое рандомизированное плацебо-контролируемое исследование симптом- и структурно-модифицирующего действия препарата Алфлутоп у больных остеоартрозом коленных суставов. Сообщение 1 — оценка симптом-модифицирующего действия препарата. Научно-практическая ревматология. 2013;51(5):532–538. DOI: 10.14412/1995-4484-2013-1545. [Alekseeva L.I., Sharapova E.P., Taskina E.A. et al. A multicenter, blind, randomized, placebo-controlled study of the symptom and structurally modifying action of Alflutop in patients with osteoarthritis of the knee. Message 1 — assessment of the symptom-modifying effect of the drug. Scientific and practical rheumatology. 2013;51(5):532-538. DOI: 10.14412/1995-4484-2013-1545 (in Russ.)].
16. Алексеева Л.И., Шарапова Е.П., Таскина Е.А. и др. Многоцентровое слепое рандомизированное плацебо-контролируемое исследование симптом- и структурно-модифицирующего действия препарата Алфлутоп у больных остеоартрозом коленных суставов. Сообщение 2 — оценка структурно-модифицирующего действия препарата. Научно-практическая ревматология. 2014;52(2):174–177. [Alekseeva L.I., Sharapova E.P., Taskina E.A. et al. A multicenter, blind, randomized, placebo-controlled study of the symptom and structurally modifying action of Alflutop in patients with osteoarthritis of the knee. Message 2 — assessment of the structurally modifying effect of the drug. Scientific and practical rheumatology. 2014;52(2):174–177 (in Russ.)].
17. Алексеева Л.И., Таскина Е.А., Лила А.М. и др. Многоцентровое проспективное рандомизированное исследование эффективности и безопасности препарата Алфлутоп® в альтернирующем режиме по сравнению со стандартным режимом. Сообщение 1: оценка эффективности препарата при различных схемах применения. Современная ревматология. 2019;13(3):51–59. DOI: 10.14412/1996-7012-2019-3-51-59. [Alekseeva L.I., Taskina E.A., Lila A.M. et al. A multicenter, prospective, randomized study of the efficacy and safety of Alflutop® in alternating mode compared to the standard mode. Message 1: evaluation of the effectiveness of the drug in various patterns of use. Modern rheumatology. 2019;13(3):51-59. DOI: 10.14412 / 1996-7012-2019-3-51-59 (in Russ.)].
18. Roberts E., Delgado Nunes V., Buckner S. et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016 Mar;75(3):552–559. DOI: 10.1136/annrheumdis-2014-206914. Epub 2015 Mar 2.
19. Blieden M., Paramore L.C., Shah D., Ben-Joseph R. A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. Expert Rev Clin Pharmacol. 2014;7(3):341–348.
20. Conaghan P.G., Arden N., Avouac B. et al. Safety of Paracetamol in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):7–14. DOI: 10.1007/s40266-019-00658-9.
21. Zeng C., Wei J., Persson M.S.M. et al. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. Br J Sports Med. 2018 May;52(10):642–650. DOI: 10.1136/bjsports-2017-098043.
22. Martel-Pelletier J., Barr A.J., Cicuttini F.M. et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. DOI: 10.1038/nrdp.2016.72.
23. Honvo G., Leclercq V., Geerinck A. et al. Safety of topical non-steroidal antiinflammatory drugs in osteoarthritis: outcomes of a systematic review and metaanalysis. Drugs Aging. 2019;36(Suppl 1):45–64. DOI: 10.1007/s4026 6-019-00661-0.
24. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N., Emberson J. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. DOI: 10.1016/S0140-6736(13)60900-9.
25. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N., Emberson J. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. DOI: 10.1016/S0140-6736(13)60900-9.
26. Curtis E., Fuggle N., Shaw S. et al. Safety of cyclo-oxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl. 1):25–44. DOI:10.1136/bmj.325.7365.619.
27. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(Прил 1):1–29. doi.org/10.14412/rjtao20180. [Karateev A.E., Nasonov E.L., Ivashkin V.T. Rational use of non-steroidal anti-inflammatory drugs. Clinical recommendations. Scientific and practical rheumatology. 2018; 56 (Appendix 1): 1–29. doi.org/10.14412/rjtao20180 (in Russ.)].
28. Gunter B.R., Butler K.A., Wallace R.L. et al. Non-steroidal antiinflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42(1):27–38. DOI: 10.1111/jcpt.12484.
29. Bally M., Beauchamp M.E., Abrahamowicz M. et al. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf. 2018;27(1):69–77. DOI: 10.1002/pds.4358.
30. Стребкова Е.А., Алексеева Л.И. Эффективность внутрисуставной терапии препаратами гиалуроновой кислоты у больных остеоартритом. Современная ревматология. 2019;13(2):96–104. DOI: 10.14412/1996-7012-2019-2-96-104.
31. Campbell K.A., Erickson B.J., Saltzman B.M. et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthritis of the knee: a systematic review of overlapping meta-analyses. Arthroscopy 2015;31(10):2036–2045. DOI: 10.1016/j. arthro.2015.03.030. e14.
32. Xing D., Wang B., Liu Q. et al. Intra-articular hyaluronic acid in treating knee osteoarthritis: a PRISMA-compliant systematic review of overlapping meta-analysis. Sci Rep 2016;6:32790. DOI: 10.1038/srep32790.
33. Concoff A., Sancheti P., Niazi F. et al. The efficacy of multiple versus single hyaluronic acid injections: a systematic review and meta-analysis. BMC Musculoskelet Disord 2017;18(1):542. DOI: 10.1186/s12891-017-1897-2.
34. Altman R., Hackel J., Niazi F. et al. Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis: A systematic review. Semin Arthritis Rheum. 2018 Oct;48(2):168–175. DOI: 10.1016/j.semarthrit.2018.01.009.
35. Jü ni P., Hari R., Rutjes A.W. et al. Intraarticular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015;(10): CD005328. DOI: 10.1002/14651858. CD005328.pub3.
36. Avouac J., Gossec L., Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007;15(8):957–965. DOI: 10.1016/j.joca.2007.02.006.
37. Schaefert R., Welsch P., Klose P. et al. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz. 2015;29(1):47–59. DOI: 10.1007/s00482-014-1451-1.
38. Fuggle N., Curtis E., Shaw S. et al. Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):129–143. DOI: 10.1007/s40266-019-00666-9.
39. Hochberg M.C., Wohlreich M., Gaynor P. et al. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol 2012;39(2):352–358. DOI: 10.3899/jrheum.110307.
40. Wang Z.Y., Shi S.Y., Li S.J. et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. Pain Med 2015;16(7):1373–1385. DOI: 10.1111/pme.12800.
41. Uchio Y., Enomoto H., Alev L. et al. A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis. J Pain Res. 2018;11:809–821. DOI: 10.2147/JPR.S164128. eCollection 2018.
42. Risser R.C., Hochberg M.C., Gaynor P.J. et al. Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain. Osteoarthritis Cartilage 2013;21(5):691–694. DOI: 10.1016/j.joca.2013.02.007
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, аnd years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789–1858. DOI: 10.1016/S0140-6736(18)32279-7.
3. Мартынов А.И., Наумов А.В., Верткин А.Л. и др. Ведение больных с остеоартритом и коморбидностью в общей врачебной практике: мнение экспертов, основанное на доказательной медицине. Лечащий врач. 2015;04:39–46. [Martynov A.I., Naumov A.V., Vertkin A.L. et al. Management of patients with osteoarthritis and comorbidity in general medical practice: expert opinion based on evidence-based medicine. Therapist. 2015;04:39–46 (in Russ.)].
4. Veronese N., Cereda E., Maggi S. et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016 Oct;46(2):160–167. DOI: 10.1016/j.semarthrit.2016.04.002.
5. Kovari E., Kaposi A., Bekes G. et al. Comorbidity clusters in generalized osteoarthritis among female patients: A cross-sectional study. Semin Arthritis Rheum. 2019 Sep 9. pii: S0049–0172(19)30233–1. DOI: 10.1016/j.semarthrit.2019.09.001.
6. McAlindon T.E., Bannuru R.R., Sullivan M.C. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363–388. DOI: 10.1016/j.joca.2014.01.003.
7. Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578–1589. DOI: 10.1016/j.joca.2019.06.011.
8. Bruyere O., Cooper C., Pelletier J.P. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014; 44(3):253−263.
9. Bruyère O., Cooper C., Pelletier J.P. et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3–11. DOI: 10.1016/j.semarthrit.2015.11.010.
10. Bruyère O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. Semin Arthritis Rheum. 2019 Apr 30. pii: S0049–0172(19)30043–5. DOI: 10.1016/j.semarthrit.2019.04.008.
11. Gregori D., Giacovelli G., Minto C. et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA 2018;320(24):2564–2579. DOI: 10.1001/jama.2018.19319.
12. Lo Y.L., Sung K.H., Chiu C.C., Wang L.F. Chemically conjugating polyethylenimine with chondroitin sulfate to promote CD44-mediated endocytosis for gene delivery. Mol Pharm. 2013Feb 4;10(2):664–676. DOI: 10.1021/mp300432s. Epub 2013 Jan 14.
13. Духанин А.С. Симптом-модифицирующие препараты замедленного действия в лечении остеоартрита: от молекулы к клиническому эффекту (взгляд фармаколога). Современная ревматология. 2018;12(2):79–87. DOI: 10.14412/1996-7012-2018-2-79-87.
14. Reginster J.Y., Dudler J., Blicharski T., Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017;76(9):1537–1543. DOI: 10.1136/annrheumdis-2016-210860.
15. Алексеева Л.И., Шарапова Е.П., Таскина Е.А. и др. Многоцентровое слепое рандомизированное плацебо-контролируемое исследование симптом- и структурно-модифицирующего действия препарата Алфлутоп у больных остеоартрозом коленных суставов. Сообщение 1 — оценка симптом-модифицирующего действия препарата. Научно-практическая ревматология. 2013;51(5):532–538. DOI: 10.14412/1995-4484-2013-1545. [Alekseeva L.I., Sharapova E.P., Taskina E.A. et al. A multicenter, blind, randomized, placebo-controlled study of the symptom and structurally modifying action of Alflutop in patients with osteoarthritis of the knee. Message 1 — assessment of the symptom-modifying effect of the drug. Scientific and practical rheumatology. 2013;51(5):532-538. DOI: 10.14412/1995-4484-2013-1545 (in Russ.)].
16. Алексеева Л.И., Шарапова Е.П., Таскина Е.А. и др. Многоцентровое слепое рандомизированное плацебо-контролируемое исследование симптом- и структурно-модифицирующего действия препарата Алфлутоп у больных остеоартрозом коленных суставов. Сообщение 2 — оценка структурно-модифицирующего действия препарата. Научно-практическая ревматология. 2014;52(2):174–177. [Alekseeva L.I., Sharapova E.P., Taskina E.A. et al. A multicenter, blind, randomized, placebo-controlled study of the symptom and structurally modifying action of Alflutop in patients with osteoarthritis of the knee. Message 2 — assessment of the structurally modifying effect of the drug. Scientific and practical rheumatology. 2014;52(2):174–177 (in Russ.)].
17. Алексеева Л.И., Таскина Е.А., Лила А.М. и др. Многоцентровое проспективное рандомизированное исследование эффективности и безопасности препарата Алфлутоп® в альтернирующем режиме по сравнению со стандартным режимом. Сообщение 1: оценка эффективности препарата при различных схемах применения. Современная ревматология. 2019;13(3):51–59. DOI: 10.14412/1996-7012-2019-3-51-59. [Alekseeva L.I., Taskina E.A., Lila A.M. et al. A multicenter, prospective, randomized study of the efficacy and safety of Alflutop® in alternating mode compared to the standard mode. Message 1: evaluation of the effectiveness of the drug in various patterns of use. Modern rheumatology. 2019;13(3):51-59. DOI: 10.14412 / 1996-7012-2019-3-51-59 (in Russ.)].
18. Roberts E., Delgado Nunes V., Buckner S. et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016 Mar;75(3):552–559. DOI: 10.1136/annrheumdis-2014-206914. Epub 2015 Mar 2.
19. Blieden M., Paramore L.C., Shah D., Ben-Joseph R. A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. Expert Rev Clin Pharmacol. 2014;7(3):341–348.
20. Conaghan P.G., Arden N., Avouac B. et al. Safety of Paracetamol in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):7–14. DOI: 10.1007/s40266-019-00658-9.
21. Zeng C., Wei J., Persson M.S.M. et al. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. Br J Sports Med. 2018 May;52(10):642–650. DOI: 10.1136/bjsports-2017-098043.
22. Martel-Pelletier J., Barr A.J., Cicuttini F.M. et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. DOI: 10.1038/nrdp.2016.72.
23. Honvo G., Leclercq V., Geerinck A. et al. Safety of topical non-steroidal antiinflammatory drugs in osteoarthritis: outcomes of a systematic review and metaanalysis. Drugs Aging. 2019;36(Suppl 1):45–64. DOI: 10.1007/s4026 6-019-00661-0.
24. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N., Emberson J. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. DOI: 10.1016/S0140-6736(13)60900-9.
25. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N., Emberson J. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. DOI: 10.1016/S0140-6736(13)60900-9.
26. Curtis E., Fuggle N., Shaw S. et al. Safety of cyclo-oxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl. 1):25–44. DOI:10.1136/bmj.325.7365.619.
27. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(Прил 1):1–29. doi.org/10.14412/rjtao20180. [Karateev A.E., Nasonov E.L., Ivashkin V.T. Rational use of non-steroidal anti-inflammatory drugs. Clinical recommendations. Scientific and practical rheumatology. 2018; 56 (Appendix 1): 1–29. doi.org/10.14412/rjtao20180 (in Russ.)].
28. Gunter B.R., Butler K.A., Wallace R.L. et al. Non-steroidal antiinflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42(1):27–38. DOI: 10.1111/jcpt.12484.
29. Bally M., Beauchamp M.E., Abrahamowicz M. et al. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf. 2018;27(1):69–77. DOI: 10.1002/pds.4358.
30. Стребкова Е.А., Алексеева Л.И. Эффективность внутрисуставной терапии препаратами гиалуроновой кислоты у больных остеоартритом. Современная ревматология. 2019;13(2):96–104. DOI: 10.14412/1996-7012-2019-2-96-104.
31. Campbell K.A., Erickson B.J., Saltzman B.M. et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthritis of the knee: a systematic review of overlapping meta-analyses. Arthroscopy 2015;31(10):2036–2045. DOI: 10.1016/j. arthro.2015.03.030. e14.
32. Xing D., Wang B., Liu Q. et al. Intra-articular hyaluronic acid in treating knee osteoarthritis: a PRISMA-compliant systematic review of overlapping meta-analysis. Sci Rep 2016;6:32790. DOI: 10.1038/srep32790.
33. Concoff A., Sancheti P., Niazi F. et al. The efficacy of multiple versus single hyaluronic acid injections: a systematic review and meta-analysis. BMC Musculoskelet Disord 2017;18(1):542. DOI: 10.1186/s12891-017-1897-2.
34. Altman R., Hackel J., Niazi F. et al. Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis: A systematic review. Semin Arthritis Rheum. 2018 Oct;48(2):168–175. DOI: 10.1016/j.semarthrit.2018.01.009.
35. Jü ni P., Hari R., Rutjes A.W. et al. Intraarticular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015;(10): CD005328. DOI: 10.1002/14651858. CD005328.pub3.
36. Avouac J., Gossec L., Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007;15(8):957–965. DOI: 10.1016/j.joca.2007.02.006.
37. Schaefert R., Welsch P., Klose P. et al. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz. 2015;29(1):47–59. DOI: 10.1007/s00482-014-1451-1.
38. Fuggle N., Curtis E., Shaw S. et al. Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):129–143. DOI: 10.1007/s40266-019-00666-9.
39. Hochberg M.C., Wohlreich M., Gaynor P. et al. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol 2012;39(2):352–358. DOI: 10.3899/jrheum.110307.
40. Wang Z.Y., Shi S.Y., Li S.J. et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. Pain Med 2015;16(7):1373–1385. DOI: 10.1111/pme.12800.
41. Uchio Y., Enomoto H., Alev L. et al. A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis. J Pain Res. 2018;11:809–821. DOI: 10.2147/JPR.S164128. eCollection 2018.
42. Risser R.C., Hochberg M.C., Gaynor P.J. et al. Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain. Osteoarthritis Cartilage 2013;21(5):691–694. DOI: 10.1016/j.joca.2013.02.007
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
